The liver-cytokine-brain circuit in interferon-based treatment of patients with chronic viral hepatitis

Journal of Viral Hepatitis

Volumn 18, Issue 8, 2011, Pages 525-532

  Stasi, C ^a   Zignego, A L ^a   Laffi, G ^a   Rosselli, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

chronic viral hepatitis; cytokines; interferon; interleukins; psychological disorders

Indexed keywords

ANTIVIRUS AGENT; CATECHOLAMINE; CITALOPRAM; CYTOKINE; GLUCOCORTICOID; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; LEUKOTRIENE; NITRIC OXIDE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

BRAIN; CHRONIC INFLAMMATION; DEPRESSION; ENDOCRINE SYSTEM; HEPATITIS C; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; LIVER; MENTAL DISEASE; METABOLITE; MOOD DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COUNSELING; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; SUICIDAL IDEATION; SYMPTOM; VIRUS REPLICATION;

ADRENOCORTICOTROPIC HORMONE; ANTIVIRAL AGENTS; BRAIN; CENTRAL NERVOUS SYSTEM VIRAL DISEASES; CORTICOSTERONE; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MENTAL DISORDERS; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 79960682780     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01418.x     Document Type: Review

References (74)

1. Ozkan M, Corapcioglu A, Balcioglu I, et al. Psychiatric morbidity and its effect on the quality of life of patients with chronic hepatitis B and hepatitis C. Int J Psychiatry Med 2006; 36: 283-297. (Pubitemid 47105287)
2. Neri S, Pulvirenti D, Bertino G,. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b. Clin Drug Investig 2006; 26: 655-662. (Pubitemid 44627849)
3. Wichers MC, Kenis G, Koek GH, Robayes G, Nicolson NA, Maes M,. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J Psychosom Res 2007; 62: 207-214. (Pubitemid 46161588)
4. Yovtcheva SP, Rifai MA, Moles JK, Van der Linden BJ,. Psychiatric comorbidity among hepatitis-C-positive patients. Psychosomatics 2001; 42: 411-415.
5. Golden J, O'Dwyer AM, Conroy RM,. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry 2005; 27 (6): 431-438. (Pubitemid 41566070)
6. VanVlierberghe H, Adler M, Bastens B, et al. Effectiveness and tolerability of pegylated interferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C: the PegIntrust study. Acta Gastroenterol Belg 2010; 73: 5-11.
7. Sonneveld MJ, Janssen HL,. Pros and cons of peginterferon versus nucleos(t)ide analogues for treatment of chronic hepatitis B. Curr Hepat Rep 2010; 9: 91-98.
8. Fried MW,. Therapy of chronic viral hepatitis. Med Clin North Am 1996; 80: 957-972. Review. (Pubitemid 26300280)
9. Quelhas R, Lopes A,. Psychiatric problems in patients infected with hepatitis C before and during antiviral treatment with interferon-alpha: a review. J Psychiatric Pract 2009; 15: 262-281.
10. Lang JP, Meyer N, Doffoel M,. Benefits of a preventive psychiatric accompaniment in patients hepatitis C virus seropositive (HCV): prospective study concerning 39 patients. Encephale 2003; 29 (4 Pt 1): 362-365. (Pubitemid 37209902)
11. Stasi C, Orlandelli E,. Role of the brain-gut axis in the phathophysiology of Crohn's disease. Dig Dis 2008; 26: 156-166. (Pubitemid 351572141)
12. Mayer EA,. The neurobiology of stress and gastrointestinal disease. Gut 2000; 46 (6): 861.
13. Elenkov I,. Neurohormonal-cytokine interactions: implications for inflammation, common human diseases and well-being. Neurochem Int 2008; 52: 40-51. (Pubitemid 350235704)
14. Chrousos MD,. Stress, chronic inflammation, and emotional and physical well-being: concurrent effects and chronic sequelae. J Allergy Clin Immunol 2000; 106: S275-S291.
15. Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS,. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology 2009; 30: 497-521.
16. Goshen I, Yirmiya R,. Interleukin-1 (IL-1): a central regulator of stress responses. Front Neuroendocrinol 2009; 30: 30-45.
17. O'Brien SM, Scott LV, Dinan TG,. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 2004; 19: 397-403. (Pubitemid 39172804)
18. Zignego AL, Cozzi A, Carpenedo R, et al. HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment. Dig Liv Dis 2007; 39: S107-S111. (Pubitemid 47528200)
19. McAndrews MP, Farcnik K, Calen P, et al. Prevalence and significance of neurocognitive disfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41: 801-808. (Pubitemid 40462942)
20. Forton DM, Taylor-Robinson SD, Thomas HC,. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat 2003; 10: 81-86. (Pubitemid 36359844)
21. Soogoor M, Lynn HS, Donfield SM, Gomperts E, Bell TS, Daar ES,. Hepatitis C virus infection and neurocognitive function. Neurology 2006; 67: 1482-1485. (Pubitemid 44632081)
22. Goh J, Coughlan B, Quinn J, O'Keane JC, Crowe J,. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1999; 11: 833-838. (Pubitemid 29389513)
23. Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ,. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000; 49: 311-317. (Pubitemid 32123807)
24. Poynard T, Cacoub P, Ratziu V, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 2002; 9: 295-303. (Pubitemid 36002465)
25. Foster GR, Goldin RD, Thomas HC,. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-212.
26. Fishman SR, Murray JM, Eng FJ, Walewski JL, Morgello S, Branch AD,. Molecular and bioinformatic evidence of hepatitis C virus evolution in brain. J Infect Dis 2008; 197 (4): 597-607. (Pubitemid 351321539)
27. Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC,. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol 2004; 78 (10): 5170-5183. (Pubitemid 38581469)
28. Radkowski M, Bednarska A, Horban A, et al. Infection of primary human macrophages with hepatitis C virus in vitro: induction of tumour necrosis factor-alpha and interleukin 8. J Gen Virol 2004; 85: 47-59. (Pubitemid 38128869)
29. Wilkinson J, Radkowski M, Laskus T,. Hepatitis C virus neuroinvasion: identification of infected cells. J Virol 2009; 83: 1312-1319.
30. Laskus T, Radkowski M, Bednarska A, et al. Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol 2002; 76: 10064-10068. (Pubitemid 35006549)
31. Forton DM, Allsop JM, Main J, Foster JR, Thomas HC, Taylor-Robinson SD,. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001; 358: 38-39. (Pubitemid 32709741)
32. Bokemeyer M, Ding XQ, Goldbecker A, et al. Evidence for neuroinflammation and neuroprotection in HCV infection-associated encephalopathy. Gut 2010; doi:.
33. Mader I, Rauer S, Gall P, Close U,. (1)H MR spectroscopy of inflammation, infection and ischemia of the brain. Eur J Radiol 2008; 67: 250-257.
34. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM,. N-acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007; 81 (2): 89-131. (Pubitemid 46282272)
35. Neale JH, Bzdega T, Wroblewska B,. N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. Brain Res 1997; 772: 9-22.
36. Baslow MH,. N-acetylaspartate in the vertebral brain: metabolism and function. Neurochem Res 2003; 28: 941-953. (Pubitemid 36438413)
37. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 433-439. (Pubitemid 34106386)
38. Weissenborn K, Krause J, Bokemeyer M, et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004; 41: 845-851. (Pubitemid 39434316)
39. Marcus CD, Taylor-Robinson SD, Sargentoni J, et al. 1H MR spectroscopy of the brain in HIV-1-seropositive subjects: evidence for diffuse metabolic abnormalities. Metab Brain Dis 1998; 13: 123-136. (Pubitemid 28350747)
40. Meyerhoff DJ, Bloomer C, Cardenas V, Norman D, Weiner MW, Fein G,. Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients. Neurology 1999; 52: 995-1003. (Pubitemid 29161610)
41. Taylor-Robinson SD,. Applications of magnetic resonance spectroscopy to chronic liver disease. Clin Med 2001; 1: 54-60.
42. Weissenborn K, Ahl B, Fischer-Wasels D, et al. Correlations between magnetic resonance spectroscopy alterations and cerebral ammonia and glucose metabolism in cirrhotic patients with and without hepatic encephalopathy. Gut 2007; 56: 1736-1742. (Pubitemid 350206301)
43. Wilkinson J, Radkowski M, Eschbacher JM, Laskus T,. Activation of brain macrophages/microglia cells in hepatitis C infection. Gut 2010; 59: 1394-1400.
44. Besedovsky HO, del Rey A,. The cytokine-HPA axis feed-back circuit. Z Rheumatol 2000; 59 (Suppl. 2): II/26-II/30.
45. van der Meer MJ, Sweep CG, Pesmanb GJ, Tilders FJ, Hermus AR,. Chronic stimulation of the Hypothalamus-pituitary-adrenal axis in rats by interleukin 1β: central and peripheral mechanisms. Cytokine 1996; 8: 910-919. (Pubitemid 27091192)
46. Besedovsky HO, Del Rey A, Klusman I, Furukawa H, Monge Arditi G, Kabiersch A,. Cytokines as modulators of the hypothalamus-pituitary-adrenal axis. J Steroid Biochem Mol Biol 1991; 40: 613-618.
47. Chikanza IC, Grossman AB,. Reciprocal interactions between the neuroendocrine and immune systems during inflammation. Rheum Dis Clin North Am 2000; 26: 693-711.
48. del Rey A, Klusman I, Besedovsky HO,. Cytokines mediate protective stimulation of glucocorticoid output during autoimmunity: involvement of IL-1. Am J Physiol 1998; 275: 1146-1151.
49. Miller AH, Pariante CM, Pearce BD,. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv Exp Med Biol 1999; 461: 107-116.
50. Raison CL, Capuron L, Miller AH,. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24-31. (Pubitemid 43083561)
51. Swain MG, Patchev V, Vergalla J, Chrousos G, Jones EA,. Suppression of hypothalamic-pituitary-adrenal axis responsiveness to stress in a rat model of acute cholestasis. J Clin Invest 1993; 91: 1903-1908. (Pubitemid 23141458)
52. Liao J, Keiser JA, Scales WE, Kunkel SL, Kluger MJ,. Role of corticosterone in TNF and IL-6 production in isolated perfused rat liver. Am J Physiol Regul Integr Comp Physiol 1995; 268: R699-R706.
53. Burdick LM, Somani N, Somani AK,. Type I IFNs and their role in the development of autoimmune diseases. Expert Opin Drug Saf 2009; 8: 459-472.
54. Raison CL, Miller AH,. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003; 160: 1554-1565. (Pubitemid 41079539)
55. Plaut M,. Lymphocyte hormone receptors. Annu Rev Immunol 1987; 5: 621-669.
56. Carr DJ, Rogers TJ, Weber RJ,. The relevance of opioids and opioid receptors on immunocompetence and immune homeostasis. Proc Soc Exp Biol Med 1996; 213: 248-257.
57. Swain MGI,. Stress and hepatic inflammation. Am J Physiol Gastrointest Liver Physiol 2000; 279: G1135-G1138.
58. Chida Y, Sudo N, Kubo C,. Does stress exacerbate liver diseases? J Gastroenterol Hepatol 2006; 21: 202-208.
59. Jung BD, Kimura K, Kitamura H, et al. Norepinephrine stimulates interleukin-6 mRNA expression in primary outlined rat hepatocytes. J Biochem 2000; 127: 205-209. (Pubitemid 30136902)
60. Fukudo S, Suzuki J, Tanaka Y, Iwahashi S, Nomura T,. Impact of stress on alcoholic liver injury; a histopathological study. J Psychosom Res 1989; 33: 515-521. (Pubitemid 19243076)
61. Singh VK,. Stimulatory effect of corticotropin-releasing neurohormone on human lymphocyte proliferation and interleukin-2 receptor expression. J Neuroimmunol 1989; 23: 257-262. (Pubitemid 19190782)
62. Singh VK, Leu SJ,. Enhancing effect of corticotropin-releasing neurohormone on the production of interleukin-1 and interleukin-2. Neurosci Lett 1990; 120: 151-154.
63. Heim C, Ehlert U, Hellhammer DH,. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology 2000; 25: 1-35. (Pubitemid 29490865)
64. Plotsky PM, Owens MJ, Nemeroff CB,. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr Clin North Am 1998; 21: 293-307.
65. Brooke SM, de Haas-Johnson AM, Kaplan J, Manuck SB, Salposky RM,. Dexamethasone resistance among nonhuman primates associated with a selective decrease of glucocorticoid receptors in the hippocampus and a history of social instability. Neuroendocrinology 1994; 60: 134-140. (Pubitemid 24222461)
66. Maes M, Stevens W, DeClerck L, et al. Immune disorders in depression: higher T helper/T suppressor-cytotoxic cell ratio. Acta Psychiatr Scand 1992; 86: 423-431.
67. Gehring S, Kullmer U, Koeppelmann S, Gerner P, Wintermeyer P, Wirth S,. Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-α. World J Gastroenterol 2006; 12: 5787-5792. (Pubitemid 44594245)
68. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995; 132: 587-593.
69. Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147: 1577-1580. (Pubitemid 17138838)
70. Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willenbring ML,. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry 2004; 26: 237-240. (Pubitemid 38581929)
71. Loftis JM, Huckans M, Ruimy S, Hinrichs DJ, Hauser P,. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci Lett 2008; 430: 264-268.
72. Cozzi A, Zignego AL, Carpendo AR, et al. Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. J Viral Hepat 2006; 13: 402-408. (Pubitemid 44030262)
73. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42: 793-798. (Pubitemid 40693194)
74. Schäfer A, Scheurlen M, Seufert J, et al. Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression. J Hepatol 2010; 52: 10-15.